In this study, the authors demonstrated for the first time that empaglifozin treatment was able to improve glycemic levels and pathophysiological changes in metabolic syndrome, in addition to reducing NLRP3 complex activation, with IL-1β inhibition in a dose-dependent manner. The gene discussed is NLRP3; the disease is metabolic syndrome.